Current and innovative emerging therapies for porphyrias with hepatic involvement

Antonio Fontanellas, Matías A. Ávila, Karl Anderson, Jean Charles Deybach

Research output: Contribution to journalReview article

Abstract

Porphyrias are rare inherited disorders caused by specific enzyme dysfunctions in the haem synthesis pathway, which result in abnormal accumulation of specific pathway intermediates. The symptoms depend upon the chemical characteristics of these substances. Porphyrins are photoreactive and cause photocutaneous lesions on sunlight-exposed areas, whereas accumulation of porphyrin precursors is related to acute neurovisceral attacks. Current therapies are suboptimal and mostly address symptoms rather than underlying disease mechanisms. Advances in the understanding of the molecular bases and pathogenesis of porphyrias have paved the way for the development of new therapeutic strategies. In this Clinical Trial Watch we summarise the basic principles of these emerging approaches and what is currently known about their application to porphyrias of hepatic origin or with hepatic involvement.

Original languageEnglish (US)
JournalJournal of hepatology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Hepatic Porphyria
Porphyrias
Investigational Therapies
Porphyrins
Sunlight
Heme
Clinical Trials
Liver
Enzymes
Therapeutics

Keywords

  • Antisense oligonucleotide therapy
  • Direct-acting antiviral agents and PCT
  • Hematopoietic-stem-cell-based gene therapy
  • Heme synthesis
  • Lentiviral vectors
  • Liver gene therapy
  • Melanogenesis stimulator
  • mRNA therapy
  • Porphyrias
  • RNA interference technology

ASJC Scopus subject areas

  • Hepatology

Cite this

Current and innovative emerging therapies for porphyrias with hepatic involvement. / Fontanellas, Antonio; Ávila, Matías A.; Anderson, Karl; Deybach, Jean Charles.

In: Journal of hepatology, 01.01.2019.

Research output: Contribution to journalReview article

Fontanellas, Antonio ; Ávila, Matías A. ; Anderson, Karl ; Deybach, Jean Charles. / Current and innovative emerging therapies for porphyrias with hepatic involvement. In: Journal of hepatology. 2019.
@article{67f9ac7dffc249f7b9202bfddc1d2cf3,
title = "Current and innovative emerging therapies for porphyrias with hepatic involvement",
abstract = "Porphyrias are rare inherited disorders caused by specific enzyme dysfunctions in the haem synthesis pathway, which result in abnormal accumulation of specific pathway intermediates. The symptoms depend upon the chemical characteristics of these substances. Porphyrins are photoreactive and cause photocutaneous lesions on sunlight-exposed areas, whereas accumulation of porphyrin precursors is related to acute neurovisceral attacks. Current therapies are suboptimal and mostly address symptoms rather than underlying disease mechanisms. Advances in the understanding of the molecular bases and pathogenesis of porphyrias have paved the way for the development of new therapeutic strategies. In this Clinical Trial Watch we summarise the basic principles of these emerging approaches and what is currently known about their application to porphyrias of hepatic origin or with hepatic involvement.",
keywords = "Antisense oligonucleotide therapy, Direct-acting antiviral agents and PCT, Hematopoietic-stem-cell-based gene therapy, Heme synthesis, Lentiviral vectors, Liver gene therapy, Melanogenesis stimulator, mRNA therapy, Porphyrias, RNA interference technology",
author = "Antonio Fontanellas and {\'A}vila, {Mat{\'i}as A.} and Karl Anderson and Deybach, {Jean Charles}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jhep.2019.05.003",
language = "English (US)",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",

}

TY - JOUR

T1 - Current and innovative emerging therapies for porphyrias with hepatic involvement

AU - Fontanellas, Antonio

AU - Ávila, Matías A.

AU - Anderson, Karl

AU - Deybach, Jean Charles

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Porphyrias are rare inherited disorders caused by specific enzyme dysfunctions in the haem synthesis pathway, which result in abnormal accumulation of specific pathway intermediates. The symptoms depend upon the chemical characteristics of these substances. Porphyrins are photoreactive and cause photocutaneous lesions on sunlight-exposed areas, whereas accumulation of porphyrin precursors is related to acute neurovisceral attacks. Current therapies are suboptimal and mostly address symptoms rather than underlying disease mechanisms. Advances in the understanding of the molecular bases and pathogenesis of porphyrias have paved the way for the development of new therapeutic strategies. In this Clinical Trial Watch we summarise the basic principles of these emerging approaches and what is currently known about their application to porphyrias of hepatic origin or with hepatic involvement.

AB - Porphyrias are rare inherited disorders caused by specific enzyme dysfunctions in the haem synthesis pathway, which result in abnormal accumulation of specific pathway intermediates. The symptoms depend upon the chemical characteristics of these substances. Porphyrins are photoreactive and cause photocutaneous lesions on sunlight-exposed areas, whereas accumulation of porphyrin precursors is related to acute neurovisceral attacks. Current therapies are suboptimal and mostly address symptoms rather than underlying disease mechanisms. Advances in the understanding of the molecular bases and pathogenesis of porphyrias have paved the way for the development of new therapeutic strategies. In this Clinical Trial Watch we summarise the basic principles of these emerging approaches and what is currently known about their application to porphyrias of hepatic origin or with hepatic involvement.

KW - Antisense oligonucleotide therapy

KW - Direct-acting antiviral agents and PCT

KW - Hematopoietic-stem-cell-based gene therapy

KW - Heme synthesis

KW - Lentiviral vectors

KW - Liver gene therapy

KW - Melanogenesis stimulator

KW - mRNA therapy

KW - Porphyrias

KW - RNA interference technology

UR - http://www.scopus.com/inward/record.url?scp=85067061936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067061936&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2019.05.003

DO - 10.1016/j.jhep.2019.05.003

M3 - Review article

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

ER -